Latest cancer news stories and articles
Sunday 06 July, 2008
coming soon...
coming soon...
Health related products & services:
Latest cancer news stories and articles
See also : Alternative medicine news | Alzheimers news | back pain news | Cancer news | Latest depression News | Diabetes news | Diet news | Exercise and fitness news | Healthy eating news | Vitamin news
| 07/06/2008 01:00 PM |
|
|
|
Cells from mice created using genetically reprogrammed cells can be triggered via drug administration to enter an embryonic-stem-cell-like state without the need for further direct genetic manipulation. This technical advancement enables creation of large numbers of genetically identical cells that can be reprogrammed to an embryonic-stem-cell-like state simply by exposure to a drug. Researchers can exploit such cells to decipher and improve the reprogramming process.
|
| 07/06/2008 07:00 AM |
|
|
|
Thyroid cancer that has spread to distant sites has a poor prognosis, but an experimental drug that inhibits tumor blood vessel formation can slow disease progression in some patients, according to a study in the New England Journal of Medicine.
|
| 07/06/2008 07:00 AM |
|
|
|
"TIGA," the new high-tech imaging center at the University of Heidelberg provides deep insights: a high-tech robot makes it possible for the first time to automatically reproduce and evaluate tissue slices only micromillimeters thick -- an important aid for researchers in understanding cancer or in following in detail the effect of treatment on cells and tissue.
|
| 07/06/2008 07:00 AM |
|
|
|
Cancer clinicians should understand and consider the economic impact of new interventions, which often have substantial costs, according to a new report.
|
| 07/05/2008 11:00 PM |
|
|
|
Men who develop breast cancer are often not treated until the disease has spread to the point that treatment becomes difficult, new results show. Although most breast cancer patients are women, men make up roughly 1 percent of cases.
|
| 07/05/2008 11:00 PM |
|
|
|
Counting the number of tumor cells circulating in the bloodstream of patients with castration-resistant prostate cancer can accurately predict how well they are responding to treatment, new results show. Researchers showed that changes in the number of circulating tumor cells predicted the outcome after chemotherapy in this hard to treat cancer.
|
| 07/05/2008 07:00 AM |
|
|
|
When tumor cells acquire the capacity to move around and invade other tissues, there is a risk of metastases and cancer treatment becomes more difficult. Scientists have just discovered how breast cancer cells break the bonds that tether them to the tumor.
|
| 07/04/2008 07:00 PM |
|
|
|
A microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy.
|
| 07/04/2008 07:00 AM |
|
|
|
Each day, a staggering number of cells perform a feat that still amazes researchers with its complexity: they divide to produce perfect replicas of each other. The process is called mitosis, and an inability to control it is one of the hallmarks of cancer. Researchers have discovered a novel biochemical activity involved in controlling cell division, which they've called the mitotic checkpoint factor 2. While the proteins involved in MCF2 remain to be determined, their findings offer insight into a fundamental question of biology, which may also help to increase the efficiency of cancer drugs like gemcitabine or paclitaxel.
|
| 07/03/2008 07:00 PM |
|
|
|
The molecular and biochemical mechanism of action of unique cytokine gene found to induce potent bystander antitumor effects in animal models and in Phase I clinical trials has been identified. Researchers have uncovered how a gene, melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), induces a bystander effect that kills cancer cells not directly receiving mda-7/IL-24 without harming healthy ones, a discovery that could lead to new therapeutic strategies to fight metastatic disease.
|
| 07/02/2008 11:00 PM |
|
|
|
Scientists have solved the structure of a class of proteins known as sodium glucose co-transporters, which pump glucose into cells. The solution of the SGLT structure will accelerate development of new drugs designed to treat patients with diabetes and cancer. The journal Science publishes the findings.
|
| 07/02/2008 07:00 PM |
|
|
|
For the first time, a research group has provided an explanation of how eating broccoli might reduce cancer risk based upon studies in men, as opposed to trying to extrapolate from animal models. Prostate cancer is the most common non-skin cancer for males in western countries. The research has provided an insight into why eating broccoli can help men stay healthy.
|
| 07/02/2008 01:00 PM |
|
|
|
For men, one of the leading causes of death from cancer is prostate cancer that has spread to a second site (something known as metastatic prostate cancer). Defining the molecular mechanisms by which the initial tumor becomes able to spread to a new site (a process known as metastasis) is likely to help clinicians predict an individual's chance of survival and help researchers develop new therapies.
|
| 07/02/2008 10:00 AM |
|
|
|
Scientists at the Stanford University School of Medicine report that lowering levels of one cancer signal under a specific threshold reverses this process in mice, returning tumor cells to their normal, healthy state.
|
| 07/01/2008 11:00 PM |
|
|
|
Medical researchers are using high-powered computers to determine how substances known as recombinant immunotoxins can best be modified in order to attack and kill malignant tumors while doing minimal harm to a patient's healthy cells.
|
| 07/01/2008 07:00 PM |
|
|
|
As bombs burst in air this July 4, chances are that sunburn will be the red glare that most folks see -- and feel. But unfortunately, even when there is no burn, the effects of the sun's ultraviolet rays can have deadly consequences. Thanks to new research scientists now know why UVB light is more likely to cause skin cancer than UVA light.
|
| 06/30/2008 11:00 PM |
|
|
|
The Wellcome Trust Sanger Institute has sequenced the equivalent of 300 human genomes in just over six months. The Institute has just reached the staggering total of 1,000,000,000,000 letters of genetic code that will be read by researchers worldwide, helping them to understand the role of genes in health and disease. Scientists will be able to answer questions unthinkable even a few years ago and human medical genetics will be transformed.
|
| 06/30/2008 11:00 PM |
|
|
|
The first research to look at recent trends in European cancer incidence, mortality and survival together has shown that cancer prevention and management in Europe is moving in the right direction. However, the research reveals that variations between countries in policies for mass screening, access to health care and treatment are reflected in the different cancer rates.
|
| 06/30/2008 01:00 PM |
|
|
|
The first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, shows promising anticancer results in mice, report researchers from Children's Hospital Boston.
|
| 06/30/2008 07:00 AM |
|
|
|
Scientists are about to embark on a human trial to test whether a new cancer treatment will be as effective at eradicating cancer in humans as it has proven to be in mice.
|
| 06/30/2008 01:00 AM |
|
|
|
New research has shown that Sorafenib, an orally administered pharmaceutical medicine, results in patients with primary hepatocarcinomas to live 40 percent more on average compared to those not taking the drug.
|
| 06/28/2008 07:00 PM |
|
|
|
A blue curing light used to harden dental fillings also may stunt tumor growth, Medical College of Georgia researchers say.
|
| 06/28/2008 07:00 PM |
|
|
|
A new study shows the potential to pre-target the treatment of cancer cells -- bringing personalized medicine one step closer from the laboratory to patients. By combining new molecular imaging techniques with targeted therapy, pre-targeting offers cancer patients a more individualized treatment that can increase the effectiveness of therapies and minimize discomfort experienced during treatment.
|
| 06/27/2008 04:00 PM |
|
|
|
A new large, prospective population-based study confirms an inverse relationship between coffee consumption and liver cancer risk. The study also found that higher levels of gamma-glutamyltransferase in the blood were associated with an increased risk of developing the disease.
|
| 06/27/2008 04:00 PM |
|
|
|
Scientists report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth. The researchers say the growth-stimulating molecule called p110beta -- part of a cellular signaling network disrupted in several common cancers -- is a promising target for novel cancer therapies designed to shut it down.
|
| 06/27/2008 10:00 AM |
|
|
|
Pregnancy seems to confer some protection against bladder cancer in mice, scientists have found. Female mice that had never become pregnant had approximately 15 times as much cancer in their bladders as their counterparts that had become pregnant, according to new findings by investigators at the University of Rochester Medical Center. Their work appears online as a rapid communication in the journal Urology.
|
| 06/27/2008 07:00 AM |
|
|
|
A new study helps bring scientists closer to a safe and efficient gene delivery method that doesn't involve viruses. Researchers have created a novel synthetic gene vector that packages DNA into well-defined nanostructures that allow it to efficiently deliver genes without triggering immune responses.
|
| 06/27/2008 07:00 AM |
|
|
|
People who have never smoked but whose cells cannot efficiently repair environmental insults to DNA are at higher risk of developing lung cancer than those with effective genomic repair capability.
|
| 06/27/2008 01:00 AM |
|
|
|
Expression of the CHD5 gene is frequently down-regulated in neuroblastomas, and patients whose tumors lacked CHD5 expression were more likely to have shorter event-free and overall survival compared with patients whose tumors expressed CHD5, according to a study in the June 24 issue of the Journal of the National Cancer Institute.
|
| 06/26/2008 07:00 PM |
|
|
|
A recently discovered, but not yet understood, section of chromosome 8, called 8q24, may contain at least five distinct regions that are associated with different cancers, according to a study in the June 24 issue of the Journal of the National Cancer Institute.
|
| 06/26/2008 04:00 PM |
|
|
|
The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is not associated with a reduction in the risk of melanoma, according to the results of a large cohort study in the June 24 issue of the Journal of the National Cancer Institute.
|
| 06/26/2008 01:00 PM |
|
|
|
New research explored whether ovarian cancer has a scent different from other cancers and whether working dogs could be taught to distinguish it in its different stages. Ovarian cancer has a high mortality rate, primarily due to late diagnosis. Researchers found that early-stage and low grade ovarian cancers emit the same scent as advanced tumors.
|
| 06/26/2008 01:00 PM |
|
|
|
Mice immunized with an intestinal protein developed fewer lung and liver metastases following injection with colon cancer cells than unvaccinated animals, according to a study in the June 24 issue of the Journal of the National Cancer Institute.
|
| 06/26/2008 10:00 AM |
|
|
|
Mechanical engineers have developed a laser "microscalpel" that destroys a single cell while leaving nearby cells intact, which could improve the precision of surgeries for cancer, epilepsy and other diseases.
|
| 06/26/2008 10:00 AM |
|
|
|
Taking advantage of the fact that the intestines have a separate immune system from the rest of the body, scientists have found a way to immunize mice against the development of metastasis. They have shown that mice immunized with an intestinal protein developed fewer lung and liver metastases after injection with colon cancer cells than did controls. The work may portend the development of a different kind of cancer vaccine that may help prevent recurrence.
|
| 06/26/2008 07:00 AM |
|
|
|
A biomedical engineering professor is using a concept called "grid computing" to allow the average person to donate idle computer time in a global effort to fight cancer.
|
| 06/25/2008 11:00 PM |
|
|
|
Researchers have conducted time-resolved fluorescence measurement and optical imaging studies that demonstrate the efficacy of Cytate as a fluorescence marker to detect prostate cancer. Cytate, a contrast agent that conjugates to receptors on prostate cancer cells, exhibited greater fluorescence when applied to cancerous prostate tissue as opposed to normal prostate tissue.
|
| 06/25/2008 04:00 PM |
|
|
|
Drugs known as HDAC inhibitors, which have antitumor activity and can be used to treat some forms of skin cancer and some types of leukemia, are also known to have anti-inflammatory properties, but the mechanisms by which they modulate the immune system have not been determined.
|
| 06/25/2008 01:00 PM |
|
|
|
Researchers have discovered that a protein that suppresses cell division in brain cells effectively "puts the brakes" on the dementia that comes with Alzheimer's disease. When the brakes fail, dementia results. This discovery could open the door to new ways of treating Alzheimer's disease, which affects up to half the population over the age of 85.
|
| 06/25/2008 10:00 AM |
|
|
|
Researchers have discovered an important factor in the development of B-cell lymphomas, one of the fastest growing forms of cancer. The B-cell receptor on the surface of B cells can cooperate with the MYC oncogene to accelerate the development of lymphomas. The research team also showed that disruption of signals from the B-cell receptor can inhibit growth of the tumors.
|
| 06/25/2008 07:00 AM |
|
|
|
A set of promising new anticancer agents could have unforeseen risks in individuals with heart disease, suggests research at Washington University School of Medicine in St. Louis. The anticancer drugs interfere with a biochemical process that promotes growth in some cancer cells. But the researchers showed that interfering with this biochemical process in mice with heart disease led to further deterioration of cardiac function and ultimately death.
|
| 06/25/2008 01:00 AM |
|
|
|
Drugs that target members of the EGFR family of proteins have proven effective for the treatment of certain types of cancer, including breast cancer. However, in a large number of patients for whom the treatment initially works well, the tumor recurs and is resistant to the effects of the drug.
|
| 06/24/2008 10:00 PM |
|
|
|
Lamellipodia and filopodia are dynamic surface extensions of the cell which play a pivotal role in cell migration, invasion and wound healing. Biochemists have succeeded in clarifying the interplay between the two types of protrusions in regulating both the migratory and invasive abilities of cancer cells. They hope to exploit their exciting findings for the development of more specific cancer therapies.
|
| 06/24/2008 07:00 PM |
|
|
|
Cells with irreparable DNA damage normally induce programmed cell death, or apoptosis. However, this mechanism often fails in tumor cells so that transformed cells are able to multiply and spread throughout the body. Scientists have now discovered a possible cause of this failure.
|
| 06/24/2008 07:00 PM |
|
|
|
Scientists have identified five genes involve in the metastasis of breast tumors to the lung. Of the five genes identified, the Tenascina-C gene seems to be a good therapeutic target for the treatment of metastatic breast cancer. In fact, the blocking of the expression of this gene in the animal model enabled a significant reduction, both in tumour growth and in the incidence of pulmonary metastasis.
|
| 06/24/2008 04:00 AM |
|
|
|
Researchers have identified a promising new target for autoimmune disease treatment -- a cell-surface receptor called DR3. Their research in mice, published in Immunity, suggests that blocking this receptor could slow or stop the damaging inflammation characteristic of autoimmune diseases, potentially without leaving the body vulnerable to serious infections, as many current therapies do.
|
| 06/24/2008 04:00 AM |
|
|
|
The invasion and spread of cancer cells to other parts of the body, known as metastasis, is a principal cause of death in patients diagnosed with breast cancer.
|
| 06/24/2008 01:00 AM |
|
|
|
Women's reports of persistent, recent-onset symptoms linked to ovarian cancer -- abdominal or pelvic pain, difficulty eating or feeling full quickly and abdominal bloating -- when combined with the CA125 blood test may improve the early detection of ovarian cancer by 20 percent.
|
| 07/06/2008 08:00 AM |
|
|
|
ORLANDO, FL (UroToday.com) - (Reported from the Annual Meeting of the American Urological Association) The main thrust of the presentations concerned decreasing the radiographic screening burden of patients with testis cancer. Chamin, et al, used SEER data to evaluate the risk of secondary malignancy in men with testis cancer who did or did not have a RPLND. After 14 yrs follow-up, men on a surveillance protocol for their testis cancer had a 1.
|
| 07/06/2008 02:00 AM |
|
|
|
ORLANDO, FL (UroToday.com) - (Reported from the Annual Meeting of the American Urological Association) Most of the abstracts suggested that robotic surgery is as effective as open or laparoscopic surgery regarding oncological and functional outcomes. Casey et.al., suggested that a laparoscopic cystectomy was more cost effective than open cystectomy, in part due to not needing the patient to stay in the ICU after robotic cystectomy.
|
| 07/06/2008 02:00 AM |
|
|
|
The number of people surviving some of the most common types of cancer for at least five years has doubled since the National Health Service was founded 60 years ago. Comparisons have shown that survival for colon cancer has risen dramatically from 18 per cent to 47 per cent while breast cancer survival has more than doubled from 37 per cent to 77 per cent between 1946 and 1998.
|
| 07/06/2008 02:00 AM |
|
|
|
Cervical cancer screening needs to take into account a partially-vaccinated population and new technologies, according to an editorial published in the latest edition of Medical Journal of Australia. Dr Annabelle Farnsworth, from Douglass Hanly Moir Pathology, said that although Australia has an enviable record in the control of cervical cancer, there are real benefits in incorporating new knowledge and associated technologies into screening and management of the disease.
|
| 07/05/2008 02:00 AM |
|
|
|
A randomized trial that studied the impact of the new vitespen vaccine, administered after surgery for kidney cancer, failed to demonstrate an increase in recurrence-free survival (RFS). More research is needed, according to the study authors, in order to know whether the vaccine can increase RFS if given to patients during the early stages of the disease.
|
| 07/05/2008 02:00 AM |
|
|
|
ORLANDO, FL (UroToday.com) - (Reported from the Annual Meeting of the American Urological Association) Researchers showed that KAI-1 can differentiate chromophobe renal cancers from oncocytoma. Papillary renal cancer with clear cell components is worse than pure papillary tumors. There was a general trend toward watching small renal masses rather than surgery. Small renal tumors that are destined to be metastatic have a growth rate of 0.74cm/year compared to 0.
|
| 07/05/2008 02:00 AM |
|
|
|
ORLANDO, FL (UroToday.com) - Abstract 1791 showed the importance of a repeat TURBT for T1 grade 3 tumors. If there is no residual tumor (NRT) on the repeat TURBT patients do much better than if there is residual tumor (SRT). NRT - Recurrence 17% - Progression 10% - DFS 78% SRT - Recurrence 45% - Progression 23% - DFS 50% Abstract 1695 showed that 60% of all bladder cancer deaths occur within the first 2 years of diagnosis.
|
| 07/05/2008 02:00 AM |
|
|
|
An article published in The Lancet finds that cancer patients who received a care package called "Depression Care for People with Cancer" (DCPC) had lower levels of depression than those who received the usual care (antidepressants and mental health services recommended by the cancer team).
|
| 07/05/2008 02:00 AM |
|
|
|
Twenty hematology and hematology/oncology fellows and junior faculty will begin a unique year-long education and mentoring program this summer as part of the American Society of Hematology (ASH) Clinical Research Training Institute. Each year, the Clinical Research Training Institute provides aspiring hematologists with the necessary tools to begin careers in clinical research.
|
| 07/04/2008 06:00 AM |
|
|
|
The Centers for Medicare & Medicaid Services (CMS) announced additional updates to the information it uses in determining which drugs may be covered under Medicare Part B when used to treat patients undergoing cancer treatment through chemotherapy. CMS will add Elsevier Gold Standard's Clinical Pharmacology compendium to the list of Medicare anti-cancer treatment compendia.
|
| 07/04/2008 05:00 AM |
|
|
|
Insightful updates on onco-urological issues were the focus of the 3rd ESU masterclass, which started in Barcelona on Friday 27 June. There were 150 participants who listened to a faculty of 12 internationally renowned experts in urological cancers. The European Board of Urology (EBU) organised a written examination following the masterclass which is accredited within the EU-ACME programme.
|
| 07/04/2008 02:00 AM |
|
|
|
Thyroid cancer that has spread to distant sites has a poor prognosis, but an experimental drug that inhibits tumor blood vessel formation can slow disease progression in some patients, a research team led by investigators from The University of Texas M. D. Anderson Cancer Center reports in the July 3rd edition of The New England Journal of Medicine.
|
| 07/03/2008 02:00 PM |
|
|
|
A study by an international team of researchers found that an experimental drug that stops blood vessels that feed tumors from forming was able, in a small number of patients, to slow down the progression of advanced thyroid cancer that has spread to other sites.
|
| 07/03/2008 06:00 AM |
|
|
|
More than 170 physicians and health care professionals specializing in the treatment of liver metastases gathered May 2-3 in Chicago for the fourth annual clinical symposium on liver-directed microsphere therapy. The symposium, sponsored by the Goshen Center for Cancer Care, was supported by an educational grant provided by Sirtex Medical. Sirtex manufactures SIR-Spheres microspheres, the only FDA-approved microsphere therapy for colorectal liver metastases.
|
| 07/03/2008 06:00 AM |
|
|
|
Oncolin Therapeutics, Inc., (OTCBB:OCOL) announces that a team of scientists supported by an Oncolin Sponsored Research Agreement (SRA) and lead by Professor Waldemar Priebe from The University of Texas M. D. Anderson Cancer Center (UTMDACC) has discovered a new inhibitor of glycolysis, which is superior to the other known inhibitors. These results were confirmed both in vitro as well as in vivo brain tumor models.
|
| 07/03/2008 06:00 AM |
|
|
|
Rising public awareness about breast cancer and the treatments available has greatly improved revenues in the overall breast cancer therapeutics market. To thrive in this highly competitive market, drug developers must offer drugs that improve survival rates and the quality of life. New analysis from Frost & Sullivan, U.S.
|
| 07/03/2008 06:00 AM |
|
|
|
Virginia Commonwealth University and VCU Massey Cancer Center researchers have uncovered how a gene, melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), induces a bystander effect that kills cancer cells not directly receiving mda-7/IL-24 without harming healthy ones, a discovery that could lead to new therapeutic strategies to fight metastatic disease.
|
| 07/03/2008 04:00 AM |
|
|
|
A Florida State University faculty member who uses computational techniques to evaluate a new class of cancer-killing drugs is attracting worldwide attention from other researchers. Kevin C.
|
| 07/03/2008 04:00 AM |
|
|
|
The growing number of cancer treatment options and their widely varying costs suggest an increased need for oncologists to understand economic issues in cancer care and be able to discuss these issue with their patients, according to a study by researchers at the University of Texas M.D. Anderson Cancer Center and RTI International.
|
| 07/03/2008 03:00 AM |
|
|
|
Now that school is out and the first day of summer is upon us, the cancer care experts at Texas Oncology remind Texans to "save your skin" by outsmarting the sun when spending time outdoors. Although the most prevalent cancer in the United States today, skin cancer is also the most preventable. The majority of the more than 1 million annual U.S. cases of skin cancer are sun-related.
|
| 07/03/2008 02:00 AM |
|
|
|
Around three-quarters of children diagnosed with leukaemia will be cured of their disease, according to research published in the British Journal of Cancer* .
|
| 07/03/2008 02:00 AM |
|
|
|
Adopting just two aspects of the Mediterranean diet can cut the risk of developing cancer by 12 per cent - research published in the British Journal of Cancer* reveals.
|
| 07/02/2008 10:00 AM |
|
|
|
With the incidence of skin cancer annually on the rise, the American Pharmacists Association (APhA) encourages consumers to talk to their pharmacist about sunburn prevention, sunburn treatment and medications that increase the skin's sensitivity to the sun. Besides being medication experts, pharmacists are also knowledgeable about how to prevent and treat common summertime ailments, such as sunburns.
|
| 07/02/2008 09:00 AM |
|
|
|
Cancer clinicians should understand and consider the economic impact of new interventions, which often have substantial costs, according to a report appearing in the July/August issue of CA: A Cancer Journal for Clinicians, a peer-reviewed journal of the American Cancer Society.
|
| 07/02/2008 09:00 AM |
|
|
|
Each day, a staggering number of cells perform a feat that still amazes researchers with its complexity: they divide to produce perfect replicas of each other. The process is called mitosis, and an inability to control it is one of the hallmarks of cancer.
|
| 07/01/2008 12:00 AM |
|
|
|
NEW YORK -- Prostate cancer is the second leading cause of death among American males, but when caught early, prostate cancer has a 90% cure rate. According to Dr. David Samadi, Chief, Division of Robotics and Minimally Invasive Surgery, Department of Urology, at Mount Sinai Medical Center, "The key to fighting prostate cancer is not to wait until there are warning signs, because by then it may be too late." The tendency of prostate cancer to grow without causing noticeable symptoms leads doctors to recommend that men over 50 get screened every year. However, Dr. Samadi recommends that anyone with a strong family history of the disease or other risk factors get screened at age 40. Routine screening for prostate canc...
|
| 06/27/2008 12:00 AM |
|
|
|
DURHAM, N.C. -- Optimized biological treatment -- combining advanced antibody therapy plus chemotherapy -- offers a promising approach to the treatment of a cancer called follicular lymphoma, according to a report in the June issue of "The Oncologist." "The triple-therapy approach employing upfront chemotherapy combined with an optimized radioimmunotherapy and extended biologic treatment with antibodies may represent the best chance for prolonged disease-free survival and potential cure" of patients with follicular lymphoma, according to the new article by Dr. Franz Buchegger, Dr. Oliver Press, and colleagues from the Fred Hutchinson Cancer Research Center, Seattle, and University Hospital of Lausanne, Switzerland. F...
|
| 06/17/2008 12:00 AM |
|
|
|
MARLBOROUGH, Mass. -- EXACT Sciences Corporation today announced that a major gastroenterology journal has accepted for publication a multi-center, prospective study of EXACT's Version 2 technology for early colorectal cancer detection using stool-based DNA testing. The study, conducted by Steven H. Itzkowitz, M.D, Professor of Medicine, Mount Sinai School of Medicine and his collaborators, was also recently presented in abstract form at Digestive Disease Week (DDW) in San Diego, California. With respect to the earliest cancer stages, Dukes' A and B, the abstract data from DDW reported sensitivity above 85 percent on average, with specificity above 80 percent. Sensitivity in asymptomatic screening patients and symptomatic pa...
|
| 06/13/2008 12:00 AM |
|
|
|
WILMINGTON, Mass. -- Sirtex, a leading developer of targeted and innovative cancer therapies, will exhibit its SIR-Spheres microspheres technology at the 2008 Society of Nuclear Medicine (SNM) Annual Meeting. The meeting, to be held June 14-18 at the Convention Center in New Orleans, La., is considered the premier educational and scientific event in the nuclear medicine community. Sirtex manufactures SIR-Spheres microspheres, the only FDA-approved microsphere therapy for advanced colorectal cancer that has metastasized to the liver.(1) The scientific program includes a CME session entitled Liver-Directed Radiomicrosphere Therapy: Advances and Opportunities for Nuclear Medicine. Organized and moderated by Seza Gulec, M.D...
|
| 06/13/2008 12:00 AM |
|
|
|
Poniard Pharmaceuticals, Inc. (NASDAQ:PARD), a biopharmaceutical company focused on oncology, announced positive preliminary results from its ongoing randomized Phase 2 clinical trial in patients with metastatic colorectal cancer (CRC) and updated results from an ongoing Phase 1 CRC trial. Preliminary data suggest that picoplatin given in combination with 5-fluorouracil and leucovorin (FOLPI) and oxaliplatin given in combination with 5-fluorouracil and leucovorin (FOLFOX) may have similar anti-tumor activity in metastatic CRC (see also Colon Cancer). The Company will present the Phase 1 and 2 picoplatin data (abstract #4100) in the General Poster Session during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) at...
|
| 06/13/2008 12:00 AM |
|
|
|
Celator Pharmaceuticals reported positive results from its CPX-1 Phase 2 clinical trial in patients with advanced colorectal cancer. CPX-1 is a liposomal formulation of irinotecan and floxuridine, based on the company's proprietary CombiPlex(TM) technology. The results were presented in a poster presentation at the American Society of Clinical Oncology meeting in Chicago. The CombiPlex(TM) drug ratio technology platform is a new approach which identifies a ratio of drugs that will deliver a synergistic benefit, locks the desired ratio in a drug delivery vehicle and maintains the ratio in patients with the goal of improving clinical outcomes. The multi-center, open-label, Phase 2 study had two arms, irinotecan-na??ve (IRI-naive) and ir...
|
| 06/06/2008 12:00 AM |
|
|
|
Sanofi-aventis and GEICAM (Grupo Espanol de Investigacion en Cancer de Mama) announced that for women with high-risk node-negative early stage breast cancer adjuvant treatment (post surgery) with Taxotere(R) (docetaxel) Injection Concentrate as part of the TAC regimen (Taxotere(R), doxorubicin, cyclophosphamide) was associated with a significant improvement in Disease Free Survival (DFS) compared to a standard FAC regimen (5-Fluorouracil, doxorubicin, cyclophosphamide) in the GEICAM 9805/Target-0 study. The results will be presented at the 2008 annual meeting of the American Society of Clinical Oncology, ASCO, in Chicago (Monday June 2, 2008, 2-6 pm, poster number 1D, abstract 542). In Europe and North America, most breast cancer pati...
|
| 06/06/2008 12:00 AM |
|
|
|
The Cancer International Research Group (CIRG), a division of TRIO (Translational Research in Oncology) announced that, based on its study BCIRG 006, the U.S. Food and Drug Administration (FDA) has approved a new treatment consisting of the chemotherapeutic agents Taxotere(R) (docetaxel) and carboplatin combined with Herceptin(R) (trastuzumab) (TCH) for the adjuvant (post-surgery) treatment of HER2 (Human Epidermal growth factor Receptor 2)-positive early breast cancer. The AC-TH regimen (doxorubicin and cyclophosphamide followed by Taxotere and Herceptin), also investigated in the BCIRG 006 study, received approval at the same time. Results from the BCIRG 006 clinical trial showed that the TCH regimen reduced the risk of disease recurre...
|
| 06/06/2008 12:00 AM |
|
|
|
Agendia BV, a world leader in the rapidly evolving field of molecular diagnostics, announced that data from two studies involving its MammaPrint(R) breast cancer prognosis test will be presented at the American Society of Clinical Oncology's (ASCO) annual meeting. Collectively, these findings show that MammaPrint, a prognostic test for breast cancer recurrence using a 70-gene signature, provides important information for more effective patient management. "These studies demonstrate the clinical utility of MammaPrint in helping physicians make more informed decisions about the course of care for their patients with breast cancer," said Laura van 't Veer, Ph.D., Head of Molecular Pathology at the Netherlands Cancer Institute in Amsterdam,...
|
| 06/06/2008 12:00 AM |
|
|
|
According to an article in the June issue of Radiology, researchers at The George Washington University Medical Center in Washington, D.C. have shown that Breast-Specific Gamma Imaging (BSGI) is highly sensitive in detecting the presence of cancer. The researchers determined that BSGI was a useful detection tool and that it was as sensitive as MRI for most cancers and perhaps more sensitive for ductal carcinoma in-situ, an early stage of breast cancer. BSGI, molecular imaging of the breast utilizing a high-resolution, small-field-of-view gamma camera, is an increasingly utilized adjunct imaging modality for the diagnosis of breast cancer. Initial studies with this imaging technique report sensitivities similar to MRI with a higher specif...
|
| 06/06/2008 12:00 AM |
|
|
|
May 14, 2008 A chemical reaction in genes that control breast cancer provides a molecular clock that could one day help researchers more accurately determine a woman's risk for developing breast cancer and provide a new approach for treatment, UT Southwestern Medical Center researchers have found. In a study published in today's issue of Cancer Epidemiology Biomarkers & Prevention, scientists from UT Southwestern show that the chemical process, called methylation, is strongly correlated with breast-cancer risk and with precancerous changes in the breast cells. The researchers determined that methylation acts as a type of biological clock, indicating how many times a cell has divided. This information could aid researchers in determin...
|
| 06/06/2008 12:00 AM |
|
|
|
Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific types of metastatic breast cancer, according to a Phase II clinical trial led by researchers at The University of Texas M. D. Anderson Cancer Center. These findings are surprising and represent the first positive study for Iressa in breast cancer, as well as for the entire class of drugs known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, said Massimo Cristofanilli, M.D., the study's principal investigator. Cristofanilli will present the findings at the American Society for Clinical Oncology's (ASCO) upcoming annual m...
|
| 06/06/2008 12:00 AM |
|
|
|
IPSOGEN SA (Marseille and New Haven), a cancer profiler that develops and markets molecular diagnostic assays for blood & breast cancers, announced that researchers from the University of Texas MD Anderson Cancer Center (MDACC, Houston, TX) will present the results of two studies on the Genomic Grade index (GGi) at the ASCO Annual Meeting, held in Chicago from May 30 to June 3, 2008. The data indicate that the Genomic Grade index predicts response to chemotherapy in breast cancer. A third study extends the pronostic utility of the GGi to inflammatory breast cancer. The Genomic Grade index (GGi) is a 97-gene measure of tumor grade, a key prognostic indicator of breast cancer agressiveness closely related to cellular proliferation. Ipsogen...
|
| 06/06/2008 12:00 AM |
|
|
|
Chicago -- The interaction of sex, age and ethnicity has a significant impact on overall survival in metastatic colorectal cancer (MCRC) patients, a study led by researchers at the University of Southern California (USC) and USC/Norris Comprehensive Cancer Center suggests. While age and ethnicity are well-established factors that impact survival in colorectal cancer, the study found that gender also plays an important role in overall survival, says Andrew Hendifar, M.D., MPH, fellow in the division of hematology/oncology at the Keck School of Medicine of USC and lead author of the study. Researchers found that pre-menopausal women with metastatic colorectal cancer (18-44 years old) lived longer than younger men, while older women (75 and...
|
| 06/06/2008 12:00 AM |
|
|
|
An international study led by researchers at the John Wayne Cancer Institute at Saint John's Health Center has found that modifications to DNA found on multiple chromosomes in tumors can help to predict outcomes in patients with early-stage rectal cancer. The study, published in the May 10, 2008, issue of the Journal of Clinical Oncology, also suggests that classification of rectal cancer based upon these genetic changes should be evaluated as means of predicting reoccurrence and perhaps re-evaluating treatment strategies. Cancer of the rectum, which is diagnosed in more than 40,000 people each year, is characterized by the development of malignant cells near the end of the large colon. While rectal cancer often is discussed along wit...
|
| 07/02/2008 12:00 AM |
|
|
|
Scientists have discovered a non-invasive,
safe way to monitor lung cancer patients, though more work is needed before it's available for use in a large clinical trial.
|
| 06/25/2008 12:00 AM |
|
|
|
A new study shows that a program emphasizing patient education and support is linked to improved at-stage diagnosis.
|
| 06/19/2008 12:00 AM |
|
|
|
The US Food and Drug Administration is taking action to protect consumers from fake--and potentially harmful--cancer treatments.
|
| 06/10/2008 12:00 AM |
|
|
|
A new study shows that having a family history of colon cancer may increase your chances of fighting it.
|
| 06/02/2008 12:00 AM |
|
|
|
Results from two pioneering studies from Duke University Medical Center offer hope to patients with one of the deadliest forms of brain cancer.
|
See also: Latest health tips
Additional Health Resources
International Food Information Council
Nutrition Information Bulletin Board & Learning Experience (NIBBLE)
Diet-Plan Diagnosis: Is Yours Healthy and Safe? (Nemours Foundation)
Naturalnews.com offers news, commentary covering natural health solutions and criticism of conventional medicine.